Aequus Announces New Independent Director to its Board

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
46
Aequus Announces New Independent Director to its Board

VANCOUVER, British Columbia, July 13, 2018 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS ) (OTCQB:AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that following the completion of its Annual General Meeting held on July 10, 2018, Mr. Damien King has joined its Board of Directors to fill the seat previously held by Dr. Fotios Plakogiannis who did not stand for re-election.

Mr. King is currently the Director of Sales with Merz Pharma Canada (“Merz”) and sits as a founding member of their Senior Leadership Team. Over the past 9 years, Mr. King has been instrumental in transforming Merz from a single brand entity, to an integrated product portfolio organization with five divisions and multiple high performing teams.

“We welcome Damien to our Board. He is an industry veteran with a track record for operating and creating shareholder value within rapidly growing pharmaceutical companies. I have no doubt Damien will provide valuable strategic and operational guidance to Aequus’ Board and business, as we continue to grow our commercial division,” said Doug Janzen, Chairman and CEO of Aequus. “Damien’s addition to the Board marks another milestone in the company’s growth as we add Directors and advisors with strategic growth expertise in the Canadian pharmaceutical industry.”

Mr. Janzen continued, “I would like to personally thank Dr. Plakogiannis for his contributions to the Company as a founder and past director. We value Fotios’ contributions and expertise and look forward to continuing to engage with him as it relates to our transdermal programs.”

Aequus’ five incumbent directors, Doug Janzen, Anne Stevens, Chris Clark, Jason Flowerday and Rodoula Plakogiannis, were all re-elected as directors of the Company by shareholders at its annual general meeting held on July 10, 2018.

ABOUT AEQUUS PHARMACEUTICALS INC.

Aequus Pharmaceuticals Inc. (TSX-V: AQS ) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca .

Forward-Looking Statements:

This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the Company’s expectations of growth for its commercial division . Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully outlicense or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2018, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.

Contact Information:

Aequus Investor Relations Email: investors@aequuspharma.ca Phone: 604-336-7906

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 20

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 349

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 360

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 37

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 69

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 192

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 17

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from the 2025 Hotel Labor Costs Report for Hospitality

Updated Category News Views 191

Hotel Labor Costs and Efficiency Improvements in 2025 In a year marked by rising wages and fluctuating revenue, hotels across the United States have made significant strides in improving labor efficiency. The latest report for 2025 reveals remarkable insights into how these establishments have optimized their operations. As labor costs increased, hotels made tactical...

Continue Reading
Ritter Sport Expands Partnership with Agritask for Sustainability

Updated Category News Views 421

Ritter Sport Enhances EUDR Compliance with Agritask Ritter Sport, the renowned chocolate manufacturer, has strengthened its alliance with Agritask, a leading crop supply intelligence company. This partnership focuses on bolstering sustainability within its cocoa supply chain, especially in light of the recent European Union Deforestation Regulation (EUDR). As part of its...

Continue Reading
Investor Advocacy: Understanding Telix Pharmaceuticals' Recent Events

Updated Category News Views 240

Recent Developments at Telix Pharmaceuticals In the ever-evolving landscape of pharmaceuticals, investors constantly seek assurance regarding the stability and profitability of their chosen companies. One such company, Telix Pharmaceuticals Limited (NASDAQ: TLX), finds itself under scrutiny recently. With the increasing necessity for transparency in the healthcare sector,...

Continue Reading
Upexi's Transformative Advisory Strategy Fuels Stock Surge

Updated Category News Views 189

Upexi's Stock Performance and Strategic Direction Upexi Inc (NASDAQ:UPXI) has witnessed a remarkable rise in its stock price, showcasing a nearly 90% increase year-to-date as of the latest updates. This surge follows the company's strategic decision to form an advisory committee, announcing Arthur Hayes, a co-founder of BitMEX, as the committee's first member. This...

Continue Reading
Singapore's Economic Growth Surpasses Expectations for 2024

Updated Category News Views 324

Singapore's Economic Performance in 2024 In an impressive turn of events, Singapore's economy has shown remarkable resilience and growth, exceeding earlier forecasts. Prime Minister Lawrence Wong recently announced that the city-state achieved a 4% growth rate for its gross domestic product (GDP) in 2024, surpassing previous estimations which anticipated a moderate 3.5%...

Continue Reading